GnRH Agonist Triggering Supplemented With Hcg in Women With Poor Ovarian Response

Not Applicable

• Conditions: Women With Poor Ovarian Response
• Interventions: Drug: Ovitrel; Drug: Decapeptyl

• Registration Number: NCT02144818
• Lead Sponsor: Sheba Medical Center

Brief Summary

During the last decades, owing to the growing tendency of women to delay childbearing plans because of career and personal priorities, fertility specialists today are seeing more and more women with poor ovarian reserve and with poor ovarian response Controlled ovarian hyperstimulation (COH) is considered a important factor in the success of in vitro fertilization-embryo transfer (IVF-ET), enabling the recruitment of multiple oocytes and, thereby, resulting in more than one embryo. However, owing to the extreme variability in ovarian response to COH, in a subgroup of patients with poor ovarian response, this method may yield a very small number of follicles After succeeding in maximal recruitment of the follicles, the triggering of ovulation is extremely important in order to achieve, as many as, mature oocytes.

Several studies have reported retrieval of more mature oocytes after GnRH agonist triggering compared to the number of oocytes retrieved after hCG. Among the possible advantages of GnRH agonist for final oocyte maturation is the simultaneous induction of an FSH surge. The role of the natural mid-cycle FSH surge is not fully clear. FSH was reported to induce LH receptor formation in luteinizing granulosa cells, and to promote oocyte nuclear maturation and cumulus expansion .

Another method described to trigger ovulation is the "Dual triggering"- GnRH agonist 40 h prior to ovum pickup and hCG added 6 h after the first trigger. The dual triggering was described as the treatment in cases with recurrent empty follicles.

The aim of the present study is to evaluate three different methods of ovulation triggering in women with poor ovarian response

Detailed Description

Inclusion criteria:

* Women with low ovarian response according to the Bologna criteria, undergoing IVF treatments for this cause.

Exclusion criteria:

* Women with good ovarian response.

* Women with low ovarian response who are carriers of fragile X

Study Timeline

• Study Start: 2014-01
• Status Verified: 2014-04
• Study First Submitted: 2014-04-28
• Study First Submitted QC: 2014-05-19
• Last Update Submitted: 2014-05-19
• Study First Posted: 2014-05-22
• Last Update Posted: 2014-05-22
• Primary Completion: 2015-07
• Study Completion: 2015-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

• Women with low ovarian response according to the Bologna criteria, undergoing IVF treatments for this cause.

Read More

Exclusion Criteria

• Women with good ovarian response.
• Women with low ovarian response who are carriers of fragile X

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
hCG	Ovitrel	-
dual triggering: GnRH agonist and hCG	Ovitrel	-
GnRH agonist	Decapeptyl	-
dual triggering: GnRH agonist and hCG	Decapeptyl	-

Primary Outcome Measures

Name	Time	Method
The main outcome is the number of mature oocytes	up to 12 months
number of embryos appropriate for transfer	up to 12 month

Secondary Outcome Measures

Name	Time	Method
pregnancy rate	up to 12 months

Trial Locations

Locations (1)

Sheba medical center; 🇮🇱 Ramat Gan, Israel